PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pregabalin - Restless Leg Syndrome
PAD Profile : Pregabalin - Restless Leg Syndrome
Brand Names Include :
Lyrica
Traffic Light Status
Status 1 of 1.
Status :
Green
Important
Preferred
Formulations :
- Capsules
Important Information :
Patients with severe sleep disturbance, RLS-related / co-morbid pain or history of impulse control disorder
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Safety Information
01 August 2023
Committee Recommendations
Date
Committee Name
Narrative
07 November 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Pregabalin is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.
Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome
Please note; this is an off-label indication of a licensed medicine.
Associated BNF Codes
04. Central Nervous System
04.07.03. Neuropathic pain